key: cord-0863140-bxljk0zf
authors: Conte, Giulia; Cei, Marco; Evangelista, Isabella; Colombo, Alessandra; Vitale, Josè; Mazzone, Antonino; Mumoli, Nicola
title: The Meaning of D-Dimer value in Covid-19
date: 2021-05-20
journal: Clin Appl Thromb Hemost
DOI: 10.1177/10760296211017668
sha: e0746f8c957202be44e069821c6c68efb932346b
doc_id: 863140
cord_uid: bxljk0zf

nan

from trials in medical patients without COVID-19. Moreover, it is not known if antithrombotic prophylaxis in COVID-19 patients should be guided by risk assessment models (the standard practice in nonsurgical admitted patients before the current pandemic), or by D-dimer levels, or instead by clinical judgement alone.

In a retrospective cohort study conducted in 2 French centers, 10 consecutive patients hospitalized in medical wards non-ICU with confirmed COVID-19 and adequate thromboprophylaxis were enrolled and subjected to systematic low limb venous duplex ultrasonography. D-dimers at baseline were significantly higher in patients with deep venous thrombosis (DVT) (P < 0.001). The negative predictive value of a baseline D-dimer level < 1.0 mg/ml was 90% for VTE and 98% for pulmonary embolism (PE). The positive predictive value for VTE was 44% and 67% for D-dimer level 1.0 mg/ml and 3 mg/ml, respectively. Increased D-dimer concentrations of more than 1.0 mg/ml predict the risk of VTE.

In an other prospective study, 165 consecutive patients hospitalized in non-intensive care units with diagnosis of COVID-19 pneumonia and D-dimer > 1000 ng/ml were screened for asymptomatic DVT with complete compression doppler ultrasound. 11 All but 3 patients were received standard doses of thromboprophylaxis. Twenty-three patients were diagnosed with DVT (of whom only one had proximal DVT, and 7 patients had bilateral distal DVT). In these kind of patients the D-dimer value was higher than other patients: 4527 ng/ml vs 2050 ng/ml; P < 0.001. Therefore, in patients with COVID-19 disease, higher cut-off levels for D-dimer might be necessary for the diagnosis of DVT. In reality, this may be a too narrow view of coagulopathy in COVID-19. In fact, autopsy studies have shown the presence of diffuse microthrombosis, which cannot be recognized with normal ultrasound or radiological methods, while they are instead expressed by multiorganic dysfunction. 12 Therefore, the only finding in patients with COVID-19 disease, of high values of D-dimer, does not necessarily indicate a diagnosis of DVT. However, a particularly significant increase of D-dimer value in COVID-19 patients deserves further investigation in order to rule out a possible DVT.

Instead, in the diagnosis of VTE, in the absence of concomitant COVID-19 disease, the negative predictive value of Ddimer testing is high, and a normal D-dimer level renders acute PE or DVT unlikely. On the other hand, the positive predictive value of elevated D-dimer levels is low and D-dimer testing is not useful for confirmation of PE. 13 Thus, in COVID-19 disease, D-dimer concentration provides important information on the prognosis of COVID-19 patients. Whether management based on risk stratification using D-dimers improves the risk benefit ratio of increased dose anticoagulant interventions remains unclear. Some clinicians use D-dimer value to determine the intensity of antithrombotic prophylaxis in these kind of patients; furthermore, some studies highlighted that decrease in D-dimer levels could correlate with a clinical improvement of the patients, offering an option for downgrading the anticoagulation intensity; finally, although the role of D-dimers in guiding treatment of COVID-19 is attractive, clinicians should be aware of the details of their local D-dimer tests before implementing standard cut-offs provided by others. 14

N. Mumoli, G. Conte and M. Cei were responsible for study concept. G. Conte, N. Mumoli, J. Vitale, M. Cei, I. Evangelista, A. Colombo, and A. Mazzone were responsible for acquisition of data. N. Mumoli, M. Cei, and G. Conte drafted the manuscript. N. Mumoli, G. Conte, and M. Cei were responsible for critical revision of the manuscript for important intellectual content. All authors had full access to the data and take responsibility for the accuracy of the data analysis.

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

The author(s) received no financial support for the research, authorship, and/or publication of this article.

Isabella Evangelista https://orcid.org/0000-0002-3828-1624 Nicola Mumoli https://orcid.org/0000-0001-7166-5630

SARS-CoV-2 and COVID-19: the most important research questions

Registry of arterial and venous thromboembolic complications in patients with COVID-19

Antiphospholipid antibodies in patients with COVID-19: a relevant observation?

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Characteristics of and important lessons from the Coronavirus Disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention

Dimer for venous thromboembolism diagnosis: 20 years later

Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy

ISTH interim guidance on recognition and management of coagulopathy in COVID-19

COVID-19 and haemostasis: a position paper from Italian Society on Thrombosis and Haemostasis (SISET)

Systematic assessment of venous thromboembolism in COVID-19 patients receiving thromboprophylaxis: incidence and role of D-dimer as predictive factors

Incidence of asymptomatic deep vein thrombosis in patients with COVID-19 pneumonia and elevated D-dimer levels

Immunothrombotic Dysregulation in COVID-19 Pneumonia Is Associated With Respiratory Failure and Coagulopathy

ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the

SSC Subcommittee on Fibrinolysis of the International Society on Thrombosis and Haemostasis. The need for accurate D-dimer reporting in COVID-19: communication from the ISTH SSC on fibrinolysis